var data={"title":"Gemtuzumab ozogamicin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Gemtuzumab ozogamicin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6260?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=gemtuzumab-ozogamicin-drug-information\" class=\"drug drug_general\">see &quot;Gemtuzumab ozogamicin: Drug information&quot;</a> and <a href=\"topic.htm?path=gemtuzumab-ozogamicin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Gemtuzumab ozogamicin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50615333\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Hepatotoxicity, including severe or fatal hepatic veno-occlusive disease, also known as sinusoidal obstruction syndrome, has been reported in association with the use of gemtuzumab ozogamicin as a single agent, and as part of a combination chemotherapy regimen. Monitor frequently for signs and symptoms of veno-occlusive disease after treatment with gemtuzumab ozogamicin.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50591725\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Mylotarg</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1016499\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Monoclonal Antibody</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1016531\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=gemtuzumab-ozogamicin-drug-information\" class=\"drug drug_general\">see &quot;Gemtuzumab ozogamicin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Premedicate with oral acetaminophen 15 mg/kg (maximum dose: 650 mg/dose) and oral or IV diphenhydramine 1 mg/kg (maximum dose: 50 mg/dose) 1 hour prior to infusion and oral or IV methylprednisolone 1 mg/kg 30 minutes prior to infusion. Additional acetaminophen and diphenhydramine doses may be administered every 4 hours if needed. Repeat methylprednisolone (or equivalent corticosteroid) dose for any sign of infusion-related reaction (eg, fever, chills, hypotension, dyspnea) during or within 4 hours of the infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cytoreduction is recommended prior to gemtuzumab ozogamicin administration if hyperleukocytosis (leukocyte count &gt;30,000/mm<sup>3</sup>) is present.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute myeloid leukemia CD33+, newly diagnosed (de novo) or refractory/relapse:</b> Limited data available in de novo diagnosis or as combination therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Monotherapy: Children &ge;2 years and Adolescents: IV: 3 mg/m<sup>2</sup>/dose, maximum dose: 4.5 mg/dose; administer on days as 1, 4, and 7</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Combination therapy: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Induction:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">BSA &lt;0.6 m<sup>2</sup>: IV: 0.1 mg/<b>kg</b>/dose once on day 6, administer over 2 hours in combination with cytarabine, daunorubicin, and etoposide (Cooper 2012; Gamis 2014; Guest 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">BSA &ge;0.6 m<sup>2</sup>: IV: 3 mg/m<sup>2</sup>/dose once on day 6, administer over 2 hours in combination with cytarabine, daunorubicin, and etoposide (Cooper 2012; Gamis 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Intensification course 2: </i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">BSA &lt;0.6 m<sup>2</sup>: IV: 0.1 mg/<b>kg</b>/dose once on day 7, administer over 2 hours in combination with cytarabine and mitoxantrone (Cooper 2012; Gamis 2014; Guest 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">BSA &ge;0.6 m<sup>2</sup>: IV: 3 mg/m<sup>2</sup>/dose once on day 7, administer over 2 hours in combination with cytarabine and mitoxantrone (Cooper 2012; Gamis 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Premedicate with acetaminophen 650 mg orally and diphenhydramine 50 mg orally or IV 1 hour prior to infusion, and methylprednisolone 1 mg/kg (or equivalent) orally or IV within 30 minutes prior to infusion. Additional acetaminophen and diphenhydramine doses may be administered every 4 hours if needed. Repeat methylprednisolone (or equivalent) dose for any sign of infusion-related reaction (eg, fever, chills, hypotension, dyspnea) during or within 4 hours of the infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cytoreduction is recommended prior to gemtuzumab ozogamicin administration if hyperleukocytosis (leukocyte count &gt;30,000/mm<sup>3</sup>) is present.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute myeloid leukemia (newly diagnosed): </b>IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Combination therapy: <b>Note:</b> A treatment course consists of 1 induction cycle and 2 consolidation cycles (in combination with chemotherapy).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Induction: </i>3 mg/m<sup>2</sup> (maximum: 4.5 mg/dose) on days 1, 4, and 7 (in combination with daunorubicin and cytarabine). If a second induction cycle is necessary, do NOT administer gemtuzumab ozogamicin during that cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Consolidation (2 cycles):</i> 3 mg/m<sup>2</sup> (maximum 4.5 mg/dose) on day 1 (in combination with daunorubicin and cytarabine).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Single-agent regimen: <b>Note:</b> A treatment course consists of 1 induction cycle and up to 8 cycles of continuation therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Induction: </i>6 mg/m<sup>2</sup> on day 1, followed by 3 mg/m<sup>2</sup> on day 8 (as monotherapy)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Continuation:</i> 2 mg/m<sup>2</sup> on day 1 every 4 weeks (as monotherapy) for up to 8 cycles</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute myeloid leukemia (relapsed/refractory):</b> IV: 3 mg/m<sup>2</sup> (maximum 4.5 mg/dose) on days 1, 4, and 7 (as monotherapy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nonhematologic toxicity (when administering gemtuzumab ozogamicin either as monotherapy or in combination with chemotherapy): </b>Children &ge;2 years, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Infusion-related reactions: </i>Interrupt the infusion and initiate appropriate medical and supportive care management; administer acetaminophen, diphenhydramine, and/or methylprednisolone, if needed. Upon symptom resolution, consider resuming the infusion at no more than half the rate at which the reaction occurred; repeat in the event of symptom recurrence. Permanently discontinue gemtuzumab ozogamicin for severe or life-threatening infusion reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Severe bleeding or hemorrhage: </i>May require treatment delay or permanent discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Other severe or life-threatening toxicities: </i>Delay gemtuzumab ozogamicin treatment until recovery to a severity of no more than mild; omit scheduled dose if delayed more than 2 days between sequential infusions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hematologic toxicity (when administering gemtuzumab ozogamicin in combination with chemotherapy): </b>Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Persistent thrombocytopenia: </i>If platelet count does not recover to &ge;100,000/mm<sup>3</sup> within 14 days following the anticipated start date of the consolidation cycle (14 days after hematologic recovery following previous cycle), discontinue gemtuzumab ozogamicin (do not administer during consolidation).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Persistent neutropenia:</i> If neutrophil count does not recover to &gt;500/mm<sup>3</sup> within 14 days following the anticipated start date of the consolidation cycle (14 days after hematologic recovery following previous cycle), discontinue gemtuzumab ozogamicin (do not administer during consolidation).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>Children &ge;2 years, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 89 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, data has shown that creatinine clearance in this range has no clinically significant effect on the pharmacokinetic profile.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 15 to 29 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>Children &ge;2 years, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Baseline hepatic impairment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild impairment: There are no dosage adjustments provided in the manufacturer's labeling; however, mild hepatic impairment had no clinically significant effects on the pharmacokinetics.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate (total bilirubin &gt;1.5 to 3 times ULN) and severe (total bilirubin &gt;3 times ULN) impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hepatotoxicity during treatment</i>\n      <b>:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For total bilirubin &gt;2 times ULN or AST and/or ALT &gt;2.5 times ULN: Delay gemtuzumab ozogamicin until recovery of total bilirubin to &le;2 times ULN and AST and ALT to &le;2.5 times ULN prior to each dose. Omit scheduled dose if delayed more than 2 days between sequential infusions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Veno-occlusive disease (VOD): Discontinue gemtuzumab ozogamicin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112394\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children &ge;2 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 89 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, data has shown that creatinine clearance in this range has no clinically significant effect on the pharmacokinetic profile.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 15 to 29 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112395\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children &ge;2 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Baseline hepatic impairment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild impairment: There are no dosage adjustments provided in the manufacturer's labeling; however, mild hepatic impairment had no clinically significant effects on the pharmacokinetics.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate (total bilirubin &gt;1.5 to 3 times ULN) and severe (total bilirubin &gt;3 times ULN) impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hepatotoxicity during treatment</i>\n      <b>:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For total bilirubin &gt;2 times ULN or AST and/or ALT &gt;2.5 times ULN: Delay gemtuzumab ozogamicin until recovery of total bilirubin to &le;2 times ULN and AST and ALT to &le;2.5 times ULN prior to each dose. Omit scheduled dose if delayed more than 2 days between sequential infusions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Veno-occlusive disease (VOD): Discontinue gemtuzumab ozogamicin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175882\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span><p>(For additional information <a href=\"topic.htm?path=gemtuzumab-ozogamicin-drug-information\" class=\"drug drug_general\">see &quot;Gemtuzumab ozogamicin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Premedicate with acetaminophen 650 mg orally and diphenhydramine 50 mg orally or IV 1 hour prior to infusion, and methylprednisolone 1 mg/kg (or equivalent) orally or IV within 30 minutes prior to infusion. Additional acetaminophen and diphenhydramine doses may be administered every 4 hours if needed. Repeat methylprednisolone (or equivalent) dose for any sign of infusion-related reaction (eg, fever, chills, hypotension, dyspnea) during or within 4 hours of the infusion. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cytoreduction is recommended prior to gemtuzumab ozogamicin administration if hyperleukocytosis (leukocyte count &gt;30,000/mm<sup>3</sup>) is present.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Acute myeloid leukemia (newly diagnosed): </b>IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Combination therapy: </i>Note:</b> A treatment course consists of 1 induction cycle and 2 consolidation cycles (in combination with chemotherapy).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Induction: </i>3 mg/m<sup>2</sup> (maximum 4.5 mg/dose) on days 1, 4, and 7 (in combination with daunorubicin and cytarabine). If a second induction cycle is necessary, do NOT administer gemtuzumab ozogamicin during that cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Consolidation (2 cycles):</i> 3 mg/m<sup>2</sup> (maximum 4.5 mg/dose) on day 1 (in combination with daunorubicin and cytarabine).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Single-agent regimen: </i>Note:</b> A treatment course consists of 1 induction cycle and up to 8 cycles of continuation therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Induction: </i>6 mg/m<sup>2</sup> on day 1, followed by 3 mg/m<sup>2</sup> on day 8 (as monotherapy)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Continuation:</i> 2 mg/m<sup>2</sup> on day 1 every 4 weeks (as monotherapy) for up to 8 cycles</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>\n        <b>Off-label dose:</b> Favorable cytogenetics: </i>Adults &lt;60 years: 3 mg/m<sup>2</sup> on day 1 of course 1 (in combination with induction chemotherapy) and on day 1 of course 3 (in combination with chemotherapy) (Burnett 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute myeloid leukemia (relapsed/refractory):</b> IV: 3 mg/m<sup>2</sup> (maximum 4.5 mg/dose) on days 1, 4, and 7 (as monotherapy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute promyelocytic leukemia (off-label use):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>\n        <b>Single-agent therapy (relapsed disease):</b></i> 6 mg/m<sup>2</sup> on days 1 and 15; for patients testing PCR negative after 2 doses, a third dose was administered (LoCoco 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Combination therapy (high-risk patients with newly diagnosed disease) (Ravandi 2009):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Induction:</i> 9 mg/m<sup>2</sup> as a single dose on day 1 (in combination with arsenic trioxide and tretinoin)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Post remission therapy (if arsenic trioxide or tretinoin discontinued due to toxicity):</i> 9 mg/m<sup>2</sup> once every 4 to 5 weeks until 28 weeks after complete remission.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990904\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 30 to 89 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, CrCl 30 to 89 mL/minute had no clinically significant effects on the pharmacokinetics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 15 to 29 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50988166\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Preexisting impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild impairment: There are no dosage adjustments provided in the manufacturer's labeling; however, mild hepatic impairment had no clinically significant effects on the pharmacokinetics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate (total bilirubin &gt;1.5 to 3 times ULN) and severe (total bilirubin &gt;3 times ULN) impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatotoxicity during treatment:</b> Total bilirubin &gt;2 times ULN or AST and/or ALT &gt;2.5 times ULN: Delay gemtuzumab ozogamicin until recovery of total bilirubin to &le;2 times ULN and AST and ALT to &le;2.5 times ULN prior to each dose. Omit scheduled dose if delayed more than 2 days between sequential infusions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Veno-occlusive disease (VOD):</b> Discontinue gemtuzumab ozogamicin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50591726\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mylotarg: 4.5 mg (1 ea) [contains dextran 40]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175845\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11238299\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">In Canada, gemtuzumab is available through a special access program (access information is available from Health Canada).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1016534\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Stable for 6 hours at room temperature; if refrigerated, consider time for room temperature equilibration and the infusion duration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: After premedication, infuse over 2 hours through a 0.2-micron polyethersulfone (PES) in-line filter. Protect IV bag from light during infusion using a light-blocking cover (infusion line does not need to be protected from light). Do not administer as IV push or bolus. Monitor for infusion reactions during and for at least 1 hour after the end of infusion. Do not mix or administer with other medications.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132602\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).  </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016).   </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175871\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Store in original carton to protect from light. Do not freeze. Reconstituted solutions should be used immediately or may be refrigerated for up to 1 hour (do not freeze); reconstituted solutions and diluted solutions should be protected from light. If not used immediately, solutions diluted for infusion are stable at room temperature for up to 6 hours or for up to 12 hours when refrigerated, which includes the 2-hour infusion time and (if necessary), the 1-hour time to allow the solution to come to room temperature prior to administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1016500\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of relapsed or refractory CD33-positive acute myeloid leukemia (AML) (FDA approved in ages &ge;2 years and adults); treatment of newly-diagnosed CD33-positive AML (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3401641\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Gemtuzumab ozogamicin may be confused with gemcitabine, inotuzumab ozogamicin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5930823\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiotoxicity</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Central nervous system: Fatigue, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Constipation, mucositis, nausea and vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Nephrotoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Febrile neutropenia, hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatotoxicity, hyperbilirubinemia, increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Bacterial infection, hemorrhagic cystitis, hepatic veno-occlusive disease, interstitial pneumonitis, neutropenic enterocolitis, pulmonary infection, pneumonia due to <i>Pneumocystis carinii</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175866\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to gemtuzumab ozogamicin or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175849\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Gemtuzumab ozogamicin is myelosuppressive, and prolonged thrombocytopenia (&gt;42 days post dose) has been reported. Monitor blood counts prior to each dose (and frequently after therapy completion) until resolution of cytopenias. Provide supportive care per standard practice as clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemorrhage: Life-threatening or fatal hemorrhage due to prolonged thrombocytopenia may occur with gemtuzumab ozogamicin therapy. Over 90% of patients in a clinical study experienced thrombocytopenia, with 20% experiencing grade 3 or 4 toxicity. Fatal bleeding events included cerebral, intracranial, and subdural hematomas. Monitor platelet counts prior to each dose and until resolution of cytopenias; monitor for signs/symptoms of bleeding and provide supportive care as clinically indicated. In addition to supportive care, severe bleeding, hemorrhage, or persistent thrombocytopenia may require treatment delay or permanent discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: <b>[US Boxed Warning]: Hepatotoxicity, including severe or fatal hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome, has been reported in association with the use of gemtuzumab ozogamicin as a single agent and as part of a combination chemotherapy regimen. Monitor frequently for signs and symptoms of VOD after treatment with gemtuzumab ozogamicin.</b> In one trial, the median time to VOD onset was 9 days (range: 2 to 298 days); some events occurred within 28 days of any dose, and 1 case occurred more than 28 days after the last dose. The risk for VOD may be higher in adults who receive higher gemtuzumab ozogamicin doses (as monotherapy), in patients with moderate to severe baseline hepatic impairment, in patients receiving gemtuzumab ozogamicin after hematopoietic stem cell transplant (HSCT), and in patients who receive HSCT after treatment with gemtuzumab ozogamicin. Although no relationship was found between the incidence of VOD and the time of HSCT relative to higher gemtuzumab ozogamicin doses, one clinical study recommended an interval of 2 months between the last gemtuzumab ozogamicin dose and transplant. Signs/symptoms of VOD include rapid weight gain, ascites, hepatomegaly (may be painful), and bilirubin/transaminase elevations. Monitor ALT, AST, total bilirubin, and alkaline phosphatase prior to each dose; more frequent monitoring of liver function tests and clinical symptoms is recommended in patients who develop abnormal liver function tests during therapy. Patients proceeding to HSCT after gemtuzumab ozogamicin therapy should also be monitored closely and frequently for liver function abnormalities. Hepatotoxicity may require dose interruption or therapy discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity/infusion reaction: Severe hypersensitivity reactions (including anaphylaxis) and other infusion-related reactions may occur within 24 hours of infusion; may be life-threatening or fatal. Infusion-related symptoms may include fever, chills, hypotension, tachycardia, hypoxia, and/or respiratory failure. Premedicate prior to each gemtuzumab ozogamicin dose with acetaminophen, diphenhydramine, and methylprednisolone; monitor vital signs frequently throughout infusion. Immediately interrupt infusion if infusion-related reactions develop (particularly dyspnea, bronchospasm, or hypotension). Monitor during and for at least 1 hour post infusion or until signs/symptoms resolve completely. Discontinue permanently for anaphylaxis, including severe respiratory symptoms or clinically significant hypotension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QT interval prolongation: Prolongation of the QT interval has been reported in patients treated with other calicheamicin-containing medications. Obtain ECGs and monitor electrolytes prior to therapy initiation and as clinically needed when administering gemtuzumab ozogamicin to patients with a history of (or predisposition for) QTc prolongation, who are taking medications known to prolong the QT interval, and in those with electrolyte disturbances.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Tumor lysis syndrome (including renal failure) may occur as a consequence of leukemia treatment, adequate hydration and prophylactic antihyperuricemic medication must be instituted prior to use. Other methods to lower WBC &lt;30,000 cells/mm3 may be considered (hydroxyurea or leukapheresis) to minimize the risk of tumor lysis syndrome.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Disease-related concerns:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute myeloid leukemia with adverse-risk cytogenetics: In a subgroup analysis, standard combination chemotherapy in combination with gemtuzumab ozogamicin did not improve event-free survival in patients having adverse-risk cytogenetics. Consider risk versus benefit of continuing treatment with gemtuzumab ozogamicin in combination with chemotherapy in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299395\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175854\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13174&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175867\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Based on the mechanism of action and information from animal reproduction studies, gemtuzumab ozogamicin may cause adverse effects if used during pregnancy. Pregnancy status should be evaluated prior to therapy. Women of reproductive potential should avoid becoming pregnant while receiving treatment and should use effective contraception during treatment and for at least 6 months after the last dose. Males with female partners of reproductive potential should use effective contraception during therapy and for at least 3 months after the last dose. Gemtuzumab ozogamicin may impair fertility in males and females of reproductive potential.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1016536\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor liver function tests (ALT, AST, total bilirubin, and alkaline phosphatase) prior to each dose, and more frequently if clinically indicated, particularly if sinusoidal obstruction syndrome (veno-occlusive disease) is suspected and/or in HSCT patients; blood counts frequently (before each dose and at least 3 times per week through recovery from treatment-related toxicities); serum chemistries at least 3 times per week through recovery from treatment-related toxicities; electrolytes. Verify pregnancy status in women of reproductive potential prior to therapy initiation. Obtain ECG prior to therapy initiation and as clinically needed when administering to patients with a history of (or predisposition for) QTc prolongation, who are taking medications known to prolong the QT interval, and in those with electrolyte disturbances.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monitor during and for at least 1 hour after the end of infusion for infusion-related reactions. Monitor for signs and symptoms of sinusoidal obstruction syndrome (rapid weight gain, hepatomegaly, ascites), signs/symptoms of bleeding or hemorrhage, and tumor lysis syndrome.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175848\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Gemtuzumab ozogamicin is a humanized CD-33 directed monoclonal antibody-drug conjugate, which is composed of the IgG4 kappa antibody gemtuzumab linked to a cytotoxic calicheamicin derivative. CD33 is expressed on leukemic cells in over 80% of patients with AML (Castaigne 2012). Gemtuzumab ozogamicin binds to the CD33 antigen, resulting in internalization of the antibody-antigen complex. Following internalization, the calicheamicin derivative is released inside the myeloid cell. The calicheamicin derivative binds to DNA resulting in double strand breaks, inducing cell cycle arrest and apoptosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175865\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Antibody portion: ~21.4 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Calicheamicin: ~97% to human plasma proteins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Calicheamicin is extensively metabolized, primarily through nonenzymatic reduction of the disulfide moiety</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Based on a 9 mg/m<sup>2</sup> dose: Antibody portion: 62 hours (after first dose); 90 hours (after second dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Clearance: Based on a 9 mg/m<sup>2</sup> dose: Antibody portion: 0.35 L/hour (after first dose); 0.15 L/hour (after second dose)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50643692\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Mylotarg Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4.5 mg (1): $9,840.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175868\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Mylotarg (CO, GR, JP, KR, VE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aplenc R, Alonzo TA, Gerbing RB, et al. Safety and Efficacy of Gemtuzumab Ozogamicin in Combination With Chemotherapy for Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group. <i>J Clin Oncol. </i>2008;26(14):2390-3295.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/18467731/pubmed\" target=\"_blank\" id=\"18467731\">18467731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arceci RJ, Sande J, Lange B, et al. Safety and Efficacy of Gemtuzumab Ozogamicin in Pediatric Patients With Advanced CD33+ Acute Myeloid Leukemia. <i>Blood.</i> 2005;106(4):1183-1188.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/15886328 /pubmed\" target=\"_blank\" id=\"15886328 \">15886328 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buckwalter M, Dowell JA, Korth-Bradley J, et al. Pharmacokinetics of Gemtuzumab Ozogamicin as a Single-Agent Treatment of Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia. <i>J Clin Pharmacol. </i>2004;44(8):873-880.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/15286091/pubmed\" target=\"_blank\" id=\"15286091\">15286091</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. <i>Cancer</i>. 2012;118(3):761-769.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/21766293/pubmed\" target=\"_blank\" id=\"21766293\">21766293</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children&rsquo;s Oncology Group trial AAML0531. <i>J Clin Oncol</i>. 2014;32(27):3021-3032.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/25092781/pubmed\" target=\"_blank\" id=\"25092781\">25092781</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gibson BE, Webb DK, Howman AJ, et al. Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. <i>Br J Haematol</i>. 2011;155(3):366-376.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/21902686/pubmed\" target=\"_blank\" id=\"21902686\">21902686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guest EM, Aplenc R, Sung L, et al. Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531. <i>Blood</i>. 2017;130(7):943-945.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/28674028/pubmed\" target=\"_blank\" id=\"28674028\">28674028</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mylotarg (gemtuzumab ozogamicin) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. Available at: <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zwaan CM, Reinhardt D, Corbacioglu S, et al. Gemtuzumab Ozogamicin: First Clinical Experiences in Children With Relapsed/Refractory Acute Myeloid Leukemia Treated on Compassionate-Use Basis. <i>Blood</i>. 2003; 101(10):3868-3871.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gemtuzumab-ozogamicin-pediatric-drug-information/abstract-text/12543868/pubmed\" target=\"_blank\" id=\"12543868\">12543868</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13174 Version 21.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F50615333\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F50591725\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1016499\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F1016531\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51112394\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51112395\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F175882\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990904\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50988166\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F50591726\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F175845\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11238299\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1016534\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132602\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F175871\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1016500\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3401641\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F5930823\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F175866\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F175849\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299395\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F175854\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F175867\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1016536\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F175848\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F175865\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F50643692\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F175868\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13174|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=gemtuzumab-ozogamicin-drug-information\" class=\"drug drug_general\">Gemtuzumab ozogamicin: Drug information</a></li><li><a href=\"topic.htm?path=gemtuzumab-ozogamicin-patient-drug-information\" class=\"drug drug_patient\">Gemtuzumab ozogamicin: Patient drug information</a></li></ul></div></div>","javascript":null}